Healthcare professionals' perspectives towards the digitalisation of paediatric growth hormone therapies: expert panels in Italy and Korea.

Autor:	Rivera Romero O; Electronic Technology Department, Universidad de Sevilla, Seville, Spain., Chae HW; Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Faienza MF; Unit of Endocrinology and Rare Endocrine Diseases, Pediatric Hospital Giovanni XXIII, Bari, Italy.; Department of Precision and Regenerative Medicine and Ionian Area, University of Bari 'A. Moro', Bari, Italy., Vergani E; Department of Translational Medicine and Surgery, Agostino Gemelli Polyclinic Foundation, IRCCS - Catholic University of the Sacred Heart, Rome, Italy., Cheon CK; Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Republic of Korea., Di Mase R; Pediatric Endocrinology Unit, University Hospital 'Federico II', Naples, Italy., Frasca F; Endocrinology Section, Department of Clinical and Experimental Medicine, Garibaldi Nesima Hospital, University of Catania, Catania, Italy., Lee HS; Department of Pediatrics, Ajou University School of Medicine, Suwon, Republic of Korea., Giavoli C; Endocrinology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy., Kim J; Department of Pediatrics, Dongguk University Ilsan Hospital, Goyang, Republic of Korea., Klain A; Pediatric Endocrinology Unit, Santobono Pausilipon Children's Hospital, Naples, Italy., Moon JE; Department of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea., Iezzi ML; Pediatric Department, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Yeh J; Merck Ltd., Seoul, South Korea, an affiliate of Merck KGaA, Darmstadt, Germany., Aversa A; Section of Endocrinology, Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy., Rhie YJ; Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea., Koledova E; Global Medical Affairs, Cardiometabolic and Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jul 10; Vol. 15, pp. 1419667. Date of Electronic Publication: 2024 Jul 10 (Print Publication: 2024).
DOI:	10.3389/fendo.2024.1419667
Abstrakt:	Introduction: To analyse the perspectives of healthcare professionals (HCPs) regarding the acceptance of digital health solutions for growth hormone (GH) deficiency care. This study identified factors impacting HCPs' intent to use and recommend digital solutions supporting recombinant-human growth hormone (r-hGH) therapy in Italy and Korea with a use case of connected drug delivery system (Aluetta ® with Smartdot™) integrated in a platform for GH treatment support (the Growzen™ digital health ecosystem). Methods: Participatory workshops were conducted in Rome, Italy, and Seoul, Korea, to collect the perspectives of 22 HCPs on various predefined topics. HCPs were divided into two teams, each moderated by a facilitator. The workshops progressed in five phases: introduction of the project and experts, capturing views on the current context of digitalisation, perceived usefulness and ease of use of Aluetta ® with Smartdot™, exploration of the perception of health technology evolution, and combined team recommendations. Data shared by HCPs on technology acceptance were independently analysed using thematic analysis, and relevant findings were shared and validated with experts. Results: HCPs from both Italy and Korea perceived Aluetta ® with Smartdot™ and the Growzen™ based digital health ecosystem as user-friendly, intuitive, and easy-to-use solutions. These solutions can result in increased adherence, a cost-effective healthcare system, and medication self-management. Although technology adoption and readiness may vary across countries, it was agreed that using digital solutions tailored to the needs of users may help in data-driven clinical decisions and strengthen HCP-patient relationships. Conclusion: HCPs' perspectives on the digitalisation in paediatric GH therapies suggested that digital solutions enable automatic, real-time injection data transmission to support adherence monitoring and evidence-based therapy, strengthen HCP-patient relationships, and empower patients throughout the GH treatment process. Competing Interests: All attendees (HCPs) received a fee for participation. EV received fee as consultant from Merck Serono Italy. ORR has participated in an advisory board for Merck. EK is an employee of Merck Healthcare KGaA, Darmstadt, Germany, and holds shares in the company. JY is an employee of Merck Ltd., Seoul, South Korea, an affiliate of Merck KGaA, Darmstadt, Germany. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Rivera Romero, Chae, Faienza, Vergani, Cheon, Di Mase, Frasca, Lee, Giavoli, Kim, Klain, Moon, Iezzi, Yeh, Aversa, Rhie and Koledova.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu